The second line includes symptomatic treatment with pharmacotherapy. 2 9 10 The first-line treatment is non-sedating antihistamines.
The pharmacotherapy of AD offers primarily symptomatic benefits, but does not retard disease progression.
The pharmacotherapy of AD offers primarily symptomatic benefits, and there is little or no evidence that it delays disease progression.
A number of investigators have described clinical response and symptomatic remission rates for stimulant and nonstimulant pharmacotherapy in adults with ADHD.
Pharmacotherapy for AD currently provides only symptomatic relief and mostly targets cognitive revival.
Nearly two-thirds of elderly patients treated for depression fail to achieve symptomatic remission and functional recovery with first-line pharmacotherapy.
In addition, in traditional trials of pharmacotherapy for rhinoconjunctivitis, the use of additional symptomatic medications is not permitted, while this use is allowed in immunotherapy trials.
Acquired nystagmus, a highly symptomatic consequence of damage to the substrates of oculomotor control, often is resistant to pharmacotherapy.
However, and aside from the well-described side effects of chronic anxiolytic pharmacotherapy, these treatments are not always successful as a significant proportion of patients remain symptomatic after their initial intervention [ 4, 5] and return of fear is commonly reported [ 6].
Recent research in the pharmacotherapy of Parkinson's disease (PD) has been able to provide numerous agents for the symptomatic control of motor impairments, but has failed to identify substances capable to slow down or even halt the progression of the disease.
